BRAF and melanoma: Combi-v (ClinicalTrials.gov, accessed on 28 April 2021, identifier: NCT01597908) is a phase 3, open label, double-arm, randomized-controlled clinical trial evaluating the effect of first-line dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily) combination therapy with vemurafenib (960 mg orally twice daily) monotherapy on overall survival (OS) and progression-free survival (PFS) in previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF V600E or V600K mutations (V600E/K accounts for 90% in V600) started from June 2012.